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Antibiotic-induced decreases in
the levels of microbial-derived
short-chain fatty acids correlate
with increased gastrointestinal
colonization of Candida albicans
Jack Guinan1, Shaohua Wang2, Tony R. Hazbun3,4, HariomYadav

2

& Shankar Thangamani5

Candida albicans is the fourth most common cause of systemic nosocomial infections, posing a
significant risk in immunocompromised individuals. As the majority of systemic C. albicans infections
stem from endogenous gastrointestinal (GI) colonization, understanding the mechanisms associated
with GI colonization is essential in the development of novel methods to prevent C. albicans-related
mortality. In this study, we investigated the role of microbial-derived short-chain fatty acids (SCFAs)
including acetate, butyrate, and propionate on growth, morphogenesis, and GI colonization of C.
albicans. Our results indicate that cefoperazone-treated mice susceptible to C. albicans infection had
significantly decreased levels of SCFAs in the cecal contents that correlate with a higher fungal load
in the feces. Further, using in vivo concentration of SCFAs, we demonstrated that SCFAs inhibit the
growth, germ tube, hyphae and biofilm development of C. albicans in vitro. Collectively, results from
this study suggest that antibiotic-induced decreases in the levels of SCFAs in the cecum enhances the
growth and GI colonization of C. albicans.
C. albicans, ofen present in the healthy gastrointestinal (GI) tract, is harmless to the immunocompetent human
host with its resident microbiota1,2. Tough compelling evidence suggests that disturbances in immune regulation contribute to invasive C. albicans infections, antibiotic-induced gut dysbiosis remains a major risk factor
for increased C. albicans colonization and dissemination in immunocompromised patients and individuals with
antibiotic-associated diarrhea (AAD)3–7. Administration of broad-spectrum antibiotics increases the risk of C.
albicans colonization in the gut and the source of systemic infections is ofen found to be the GI tract7–10. In addition, more than 60% of individuals with AAD test positive for C. albicans and patients treated with antibiotics
for Clostridium difcile ofen develop an episode of candidemia5,6. Taken together, these studies demonstrate
that antibiotic-induced gut dysbiosis in immunocompromised individuals and AAD patients leads to increased
colonization of C. albicans and this increased intestinal colonization predisposes high-risk patients to systemic
candidiasis11,12. Terefore, understanding the factors involved in antibiotic-induced gut dysbiosis and subsequent
GI colonization of C. albicans is critical to treat and prevent C. albicans pathogenesis.
Antibiotic treatment in mice and humans alters the composition of gut microbiota, ultimately leading to changes
in the levels of microbial-derived gut metabolites, mainly bile acids and short-chain fatty acids (SCFAs)13–16.
Alterations in the normal levels of microbial-derived bile acids and SCFAs have been implicated in the growth,
colonization, and pathogenesis of enteric pathogens including C. difcile13,14,16. Moreover, we have recently
demonstrated that microbial-derived bile acids play an important role in the GI colonization of C. albicans17,18.
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Figure 1. Cefoperazone-treated mice susceptible to C. albicans have decreased levels of SCFAs in the cecum.
C. albicans SC5314 load in fecal contents afer 5 days of infection in mice receiving sterile water with or without
cefoperazone. Fungal load (Log10 CFU/g feces) determined by CFU count (a). SCFA levels (µmol/g) in the
cecal contents from mice receiving sterile water with or without cefoperazone (b). Data is represented as
means ± SEM with n = 5–6 mice in each treatment group. Statistical signifcance was evaluated using student’s
t-test and P values (* ≤ 0.05, ** ≤ 0.01) were considered as signifcant.

However, the role of SCFAs including acetate, propionate, and butyrate–three major fatty acids produced by gut
microbiota19–21–in the GI colonization of C. albicans is poorly understood. Given the abundance of SCFAs in the
intestine, a natural habitat and invasion site for C. albicans, understanding the role of SCFAs on fungal growth,
morphogenesis and colonization will have important implications in C. albicans infections. Terefore, in this
study, we aim to understand the role of microbial-derived SCFAs in the GI colonization of C. albicans.
To investigate if antibiotic treatment alters the levels of microbial-derived SCFAs and GI colonization of C.
albicans, we treated mice with cefoperazone and determined the levels of SCFAs and the C. albicans load in the
cecal and fecal contents, respectively. Furthermore, the role of SCFAs including acetic, butyric, and propionic
acid on C. albicans growth and morphogenesis were investigated in vitro. Our results indicate that SCFAs inhibit
the growth and morphogenesis of C. albicans and may potentially regulate the GI colonization of this fungal
pathogen.

Results

Antibiotic-treated, C. albicans-susceptible mice have significantly reduced levels of SCFAs
in the cecum. To determine the impact of antibiotic treatment on cecal SCFA levels and C. albicans load,

groups of mice were treated with sterile water with or without cefoperazone for 7 days. Afer 7 days of antibiotic
treatment, mice were euthanized for cecal SCFA analysis. Another set of control or antibiotic-treated mice were
infected with C. albicans and their fecal CFU load was determined afer 5 days of infection.
Results indicate that cefoperazone-treated mice had a signifcantly higher C. albicans load in the feces afer 5
days of infection. Cefoperazone-treated mice had an almost 3 log10 increase in fungal load in the feces compared
to control groups (Fig. 1a). Next we determined the SCFA levels in cefoperazone-treated C. albicans susceptible group and non-treated control group that are resistant to C. albicans infection. Interestingly, SCFA levels
in the cecum of cefoperazone-treated mice were signifcantly decreased compared to control groups (Fig. 1b).
Te average concentration of acetic acid, butyric acid and propionic acid in the cecal content of control groups
were 36.87 ± 7.11 µmol/g, 7.52 ± 0.92 µmol/g and 8.18 ± 0.77 µmol/g respectively. However, the SCFA levels in
the cefoperazone-treated mice that are highly susceptible to C. albicans were acetic acid (16.13 ± 2.39 µmol/g),
butyric acid (1.77 ± 0.79 µmol/g) and propionic acid (1.95 ± 0.63 µmol/g) (Fig. 1b). Taken together, these results
suggest that cefoperazone-treated mice susceptible to C. albicans GI colonization had signifcantly decreased
levels of SCFAs in the cecal contents.

SCFAs inhibit the growth of C. albicans in vitro.

To investigate if in vivo levels of SCFAs in the cecal
contents have any potential role in GI colonization of C. albicans, we examined the efect of SCFAs on C. albicans
growth in vitro. We used pH-adjusted RMPI media to determine if changes in pH as a result of SCFA treatment
have any inhibitory efect on C. albicans growth. RPMI media was titrated with HCl to match the pH values
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RPMI (for growth and bioflm Assays)

RPMI + 30% FBS (for hyphal and germ tube assays)

[Acetic Acid]
(mM)

HCl-Adjusted
Controls pH

[Acetic Acid]
(mM)
Experimental pH

HCl-Adjusted
Controls pH

Experimental pH

50

3.66 ± 0.03

3.65 ± 0.05

50

—

—

25

4.05 ± 0.03

4.12 ± 0.07

25

4.68 ± 0.02

4.69 ± 0.01

12.5

4.47 ± 0.03

4.49 ± 0.04

12.5

5.46 ± 0.05

5.52 ± 0.03

6.25

5.33 ± 0.06

5.38 ± 0.05

6.25

—

—

3.125

6.36 ± 0.03

5.85 ± 0.24

3.125

—

—

0

7.00

7.00

0

>7.00

7.01 ± 0.01

Table 1. Experimental pH of RPMI supplemented with varying concentrations of acetic acid and respective pH
of HCl-adjusted pH controls. Values taken as mean ± SEM.
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Figure 2. SCFAs inhibit C. albicans growth in vitro. Growth of C. albicans strains SC 5314 (a) and ATCC 10231
(b) in the presence of SCFAs or in pH-adjusted RPMI media determined by spectrophotometer analysis at an
optical density of 600 nm afer 24 and 48 hours of incubation. Experiment was repeated three times and the
three combined replicates were shown here with total n = 9 for each group. Data is represented as means ± SEM.
Statistical signifcance was evaluated using student’s t-test and P values (* ≤ 0.05, ** ≤ 0.01) were considered as
signifcant. Signifcance is shown only for data points that exhibited signifcant decreases in growth compared
to respective controls. Signifcance for pH-adjusted RPMI values was assessed using pH 7.00 as the comparative
data set; signifcance for SCFA-treated conditions was assessed using respective pH controls for each SCFA
condition in statistical analyses. Signifcance (**) for acetic acid (50 mM), butyric acid (12.5 mM and 25 mM),
and propionic acid (25 mM) indicates p ≤ 0.01 at both 24 and 48 hours in both strains.

of SCFA treatments (Table 1). Results indicate that C. albicans (ATCC 10231 and SC 5314) strains grown in a
pH ranging from 7.00 to 3.65 ± 0.05 experienced strain-dependent changes in growth in diferent pH-adjusted
RPMI media (Fig. 2a,b). C. albicans SC 5314 exhibited a 30% increase in growth at pH 3.65 ± 0.05, 4.12 ± 0.07
and 4.49 ± 0.04, and a 12% increase at pH 5.38 ± 0.05 compared to fungal cells grown in pH 7.00 RPMI control
afer 24 hours (Fig. 2a). On the other hand, C. albicans ATCC 10231 strain did not show a considerable change
in growth at pH values ranging from 7.00 to 4.12 ± 0.07. However, it exhibited a 13% decrease in growth at a pH
value of 3.65 ± 0.05 compared to pH 7.00 RPMI control (Fig. 2b). Tese results indicate that alteration in pH does
not considerably inhibit the growth of C. albicans.
Next, we determined the efect of SCFAs on C. albicans growth. In RPMI media supplemented with average
in vivo concentrations of SCFAs, C. albicans exhibited a signifcant decrease in growth compared to its respective
pH-adjusted control groups (Fig. 2a,b). Afer 24 hours of treatment with acetic acid, C. albicans (SC 5314 and
ATCC 10231) exhibited a 25–40% decrease at 12.5 mM, a 95% decrease at 25 mM, and no growth at 50 mM
(Fig. 2a,b). Butyric acid exhibited potent inhibitory activity even at lower concentrations. Butyric acid (6.25 mM)
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Figure 3. SCFAs inhibit germ tube formation. Germ tube formation in C. albicans ATCC 10231 strain in the
presence of SCFAs or pH-adjusted media supplemented with 30% FBS. Representative images of germ tubes
formed afer 2 hours in control and treatment groups determined by microscopic analysis at 40X magnifcation
(a). Quantifcation of the percent C. albicans cells with germ tubes in pH-adjusted controls; pH-adjusted
controls (12.5 mM and 25 mM) were normalized to the RPMI control (pH 7.00) (b). Quantifcation of the
percent C. albicans cells with germ tubes in SCFA treatment groups (c). SCFA treatments were normalized
to their respective pH controls. Te germ tube experiment was repeated three times and two 40X images
were taken from each replicate for each treatment group, with a minimum n = 1000 cells for each group. C.
albicans (CFU/mL) viability determined afer 2 hours of incubation in germ tube-inducing conditions (d).
Te experiment was repeated three times with n = 12 for each treatment group. Combined replicates for both
experiments are shown here. Data is represented as means ± SEM. Statistical signifcance was evaluated using
student’s t-test and P values (* ≤ 0.05, ** ≤ 0.01) were considered as signifcant.
reduced growth by 11–41%, followed by reduction of growth by 93–98% and 98–100% at 12.5 mM and 25 mM
treatments, respectively (Fig. 2a,b). A similar trend was seen with propionic acid. At a concentration of 6.25 mM,
propionic acid exhibited a 22% reduction in growth C. albicans (ATCC 10231). C. albicans (SC 5314 and ATCC
10231) further exhibited a 57–84% and 98–100% decrease in growth in the presence of 12.5 mM and 25 mM
of propionic acid, respectively (Fig. 2a,b). Further, we assessed if SCFAs possess an inhibitory activity against
C. albicans in RPMI media containing SCFAs bufered to pH 7.00. Surprinsingly, our results indicate that the
overall inhibitory efect of SCFAs was abolished when RPMI media containing SCFAs was bufered to pH 7.00
(Supplementary Fig. 1). Tese trends continued into 48 hours, with strain-dependent signifcant inhibition of
growth at varying concentrations of acetic acid (12.5–50 mM), butyric acid (6.25–25 mM), and propionic acid
(6.25–25 mM) (Fig. 2a,b). Overall, our results demonstrate that SCFAs inhibit the growth of C. albicans strains in
a concentration-dependent manner and that growth inhibition is not due to changes in pH.

SCFAs inhibit C. albicans germ tube formation.

Te impact of SCFA treatment on C. albicans germ
tube formation was determined using microscopy analysis. pH-adjusted RPMI controls were used to determine
if alterations in pH have any efect on germ tube formation. Microscopic imaging revealed that C. albicans considerably reduced the germ tube formation in pH controls for 12.5 mM (pH 5.52 ± 0.03) and 25 mM (pH 4.69 ± 0.01)
compared to the RPMI control (pH 7.01 ± 0.01) (Fig. 3a). Quantifcation of the C. albicans cells that formed germ
tubes afer 2 hours of incubation revealed a 30% decrease in germ tube formation in pH control 12.5 mM (pH
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5.52 ± 0.03) and an almost 50% decrease in pH control 25 mM (pH 4.69 ± 0.01) compared to the RPMI control
(pH 7.01 ± 0.01) (Fig. 3b). Tese results indicate that acidic pH signifcantly inhibited the germ tube formation
in C. albicans.
Although acidic pH itself was shown to be a factor in inhibiting germ tube formation, we determined the efect
of SCFAs on C. albicans germ tube formation. Interestingly, SCFAs were more potent in inhibiting the germ tube
formation compared to their respective pH-adjusted controls. Microscopic imaging of C. albicans in the presence
of SCFAs revealed a considerable decrease in germ tube formation compared to their respective pH-adjusted
controls (Fig. 3a). In addition, quantifcation of the percentage of germ tubes formed revealed that acetic acid
(25 mM) reduced germ tube formation by 50% compared to its pH control (pH 4.69 ± 0.01) (Fig. 3c). Butyric acid
(12.5 mM) and propionic acid (12.5 mM) also signifcantly inhibited germ tube formation compared to their pH
control (pH 5.52 ± 0.03), reducing germ tube formation by nearly 70% and 50%, respectively (Fig. 3c).
To determine if germ tube inhibition by SCFAs was not due to fungal cell death, C. albicans cells incubated
in the germ tube conditions were determined for cell viability. Results indicated that no signifcant decrease in
fungal cells was noticed afer 2 hours of incubation in SCFA-treated or pH-adjusted control groups (Fig. 3d).
Assessment of growth by spectrophotometer analysis under germ tube-inducing conditions showed a similar
trend (Supplementary Fig. 2a). Tese results indicate that SCFAs inhibit C. albicans germ tube formation partly
by inducing acidic conditions and through other unknown mechanisms.

SCFAs inhibit C. albicans hyphae formation. Te efect of SCFAs on C. albicans (ATCC 10231 and
SC5314) hyphae formation was evaluated using crystal violet and microscopic analyses. We used pH-adjusted
RMPI media to determine if changes in pH have any efect on C. albicans hyphae formation. Results indicate that
C. albicans ATCC 10231 grown in RPMI media at pH 7.01 ± 0.01 (RPMI control) showed massive hyphae formations (Fig. 4a). However, a considerable decrease in hyphae formation was noticed in the pH-adjusted controls
for 12.5 mM (pH 5.52 ± 0.03) and 25 mM (pH 4.69 ± 0.01) treatments (Fig. 4a). Further, a crystal violet assay
indicated that the pH-adjusted control 25 mM (pH 4.69 ± 0.01) inhibited 90% of C. albicans hyphae attachment,
followed by 75% inhibition in the pH-adjusted control 12.5 mM (pH 5.52 ± 0.03) (Fig. 4b). Taken together, the
crystal violet assay complements the fndings of microscopic observations, indicating that acidic pH not only
decreases hyphae formation but also signifcantly inhibits C. albicans hyphae attachment to polystyrene plates.
Next, we investigated the efect of SCFAs on C. albicans hyphae formation and attachment. Our results indicate that SCFAs including acetic acid (25 mM), butyric acid (12.5 mM) and propionic acid (12.5 mM) considerably decreased C. albicans hyphae formation compared to their respective pH-adjusted RPMI controls (Fig. 4a).
Further, all three SCFAs signifcantly inhibited C. albicans hyphae attachment to the polystyrene plates (Fig. 4c).
Butyric acid (12.5 mM) inhibited 90% of C. albicans hyphae attachment, followed by propionic acid (12.5 mM)
and acetic acid (25 mM) by 70 and 50%, respectively compared to their pH-adjusted controls (Fig. 4c).
To rule out if C. albicans hyphae inhibition as a result of SCFA treatment was not due to fungal cell death, C.
albicans grown under hyphae-inducing conditions in the presence or absence of SCFAs were plated onto YPD
agar plates to determine the CFU count. Results from this experiment suggest that viability of fungal cells was
not signifcantly afected in all treatment conditions compared to RPMI control (pH 7.01 ± 0.01), indicating that
decreased hyphae formation and attachment was not due to decrease in cell viability (Fig. 4d). Tis was consistent
with spectrophotometer analysis of cell growth under hyphae-inducing conditions (Supplementary Fig. 2b). A
similar trend of SCFAs inhibiting hyphae formation was observed with C. albicans SC5314 strain (Supplementary
Fig. 3). Taken together, our results indicate that SCFAs may regulate C. albicans hyphae formation and attachment
partly by altering pH levels in addition to other mechanisms.
SCFAs reduce the metabolic activity of fungal cells in C. albicans biofilm. Te efect of SCFAs on
the metabolic activity of C. albicans (ATCC 10231 and SC5314) in the bioflm was evaluated using an MTS reduction assay. In order to determine if the change in pH has any efect on the metabolic activity of fungal cells in C.
albicans bioflm, we used pH-adjusted RMPI media to determine the efect of pH on C. albicans metabolic activity
in the bioflm. Results indicate that an acidic pH signifcantly decreases the metabolic activity of fungal cells in
the C. albicans (ATCC 10231) bioflm (Fig. 5a). Te metabolic activity of fungal cells in C. albicans bioflm in the
pH-adjusted controls 12.5 mM (pH 5.52 ± 0.03) and 25 mM (pH 4.69 ± 0.01) were decreased by 25% compared
to the RPMI control (pH 7.00) (Fig. 5a).
Next, we assessed the efect of SCFAs on fungal cell metabolic activity in C. albicans bioflm. Results indicate
that SCFAs including acetic acid (25 mM), butyric acid (12.5 mM) and propionic acid (12.5 mM) signifcantly
decreased the metabolic activity of fungal cells in C. albicans bioflm compared to their respective pH-adjusted
RPMI controls (Fig. 5b). Butyric acid at 12.5 mM decreased the metabolic activity by 90%, followed by propionic
acid (12.5 mM) and acetic acid (25 mM) by 70% and 60%, respectively (Fig. 5b). Further, in order to determine
if the efect of SCFAs or pH-adjusted RPMI groups on C. albicans metabolic activity was not due to fungal cell
death, C. albicans grown under bioflm-inducing conditions were plated onto YPD agar plates to determine the
CFU count. Results indicate that the viability of fungal cells was not signifcantly afected in any treatment condition compared to RPMI control (pH 7.00), suggesting that decreased metabolic activity of fungal cells in C. albicans bioflm was not due to cell viability (Fig. 5c). Growth assessed by spectrophotometer analysis of C. albicans
under bioflm conditions showed comparable results (Supplementary Fig. 2c). A similar trend was observed with
C. albicans SC5314 strain in the inhibition of bioflm formation by SCFAs (Supplementary Fig. 4). Collectively,
results from this experiment indicate that SCFAs regulate the metabolic activity of C. albicans in the bioflm partly
by altering pH and through other mechanisms.
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Figure 4. SCFAs inhibit C. albicans hyphae formation in vitro. C. albicans ATCC 10231 was grown in the
presence of SCFAs or in pH-adjusted RPMI media supplemented with 30% FBS and examined using bright
feld microscopy at 40× (a). Quantifcation of C. albicans hyphae attachment to polystyrene plates in pHadjusted controls; pH-adjusted controls (12.5 mM and 25 mM) were normalized to the RPMI control (pH
7.00) (b). Quantifcation of C. albicans hyphae attachment to polystyrene plates in SCFA-treatment groups;
SCFA treatment groups were normalized to their respective pH controls (c). C. albicans (CFU/mL) viability
determined afer 12 hours of incubation in hyphae-inducing conditions (d). Te experiment was repeated three
times with n = 24 for the hyphae formation and n = 12 for the CFU viability determination in each treatment
group. Data is represented as means ± SEM. Statistical signifcance was evaluated using student’s t-test and P
values (* ≤ 0.05, ** ≤ 0.01) were considered as signifcant.

Discussion

Te gut microbiota plays a major role in the colonization resistance to enteric bacterial and fungal pathogens
including C. albicans22–25. While mechanisms of colonization resistance to enteric pathogens by commensal
bacteria are speculated to include immune responses, competition for nutrients, pH modulation, and synthesis
of antimicrobial and antifungal compounds17,24–27, the mechanisms associated with colonization resistance to
C. albicans remain poorly understood. Te development of efective preventative and therapeutic treatments
thus necessitates a deeper understanding of the innate mechanisms of colonization resistance to C. albicans.
Commensal bacteria produce a variety of bioactive molecules; however, SCFAs have emerged as key regulators
of gut homeostasis for colonization resistance against enteric pathogens14,16,24. Several preliminary studies have
highlighted the antifungal potential of select SCFAs28–34. However, using in vivo concentrations, the role of SCFAs
on C. albicans growth, morphogenesis and GI colonization is poorly understood. Importantly, though the inhibitory efects of SCFAs on enteric pathogens have been speculated to occur due to alterations in pH levels, this
hypothesis has not been investigated in detail, particularly in C. albicans35,36.
SCFAs including acetate, butyrate and propionate are produced as a result of bacterial fermentation in the
cecum20,21,37. SCFAs are abundant microbiota metabolites in the GI tract luminal microenvironment, where
C. albicans colonization takes place9,10,38. Acetate is the predominant SCFA present in the cecum, followed by
butyrate and propionate39–41, with the molar ratio of acetate, butyrate, and propionate typically being 60:20:20
in the human intestinal tract42,43. In mice (cecum) and humans (feces), the concentration of acetate ranges
from 30.09 ± 2.09–40.66 ± 0.122 µmol/g to 69.1 ± 5.0–73.7 ± 21.5 µmol/g39–42. Butyrate concentrations in
mice and humans remain relatively consistent, ranging from 18.52 ± 4.92–35.9 ± 10.2 µmol/g, although concentrations as low as 2.59 ± 0.31 µmol/g have been reported39–42. Propionate has been reported to range from
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Figure 5. SCFAs reduce the metabolic activity of fungal cells in the C. albicans bioflm. C. albicans ATCC 10231
was grown in the presence of SCFAs or in pH-adjusted RPMI and the metabolic activity of the fungal cells in
the bioflm was assessed using MTS assay. Percent metabolic activity of fungal cells in the bioflm formed in pHadjusted controls was determined; pH adjusted controls (12.5 mM and 25 mM) were normalized to the RPMI
control (pH 7.00) (a). Percent metabolic activity of fungal cells in the bioflm formed in SCFA-treatment groups;
SCFA treatments groups were normalized to their respective pH controls (b). C. albicans (CFU/mL) viability
determined afer 48 hours of incubation in bioflm-inducing conditions (c). All experiments were repeated three
times, with n = 18 to determine the metabolic activity in the bioflm and n = 12 for the CFU viability analysis in
each treatment group. Data is represented as means ± SEM. Statistical signifcance was evaluated using student’s
t-test and P values (* ≤ 0.05, ** ≤ 0.01) were considered as signifcant.
7.43 ± 0.16–25.3 ± 3.7 µmol/g39–42. In this study, we report that concentrations of SCFAs in untreated mice are
in agreement with these fndings39–42. Since antibiotic-induced gut dysbiosis is an important factor for the GI
colonization of C. albicans44,45, we examined if antibiotic-induced alterations in the levels of SCFAs play a role in
the GI colonization of this fungal pathogen. In this study, we found that cefoperazone-treated mice susceptible
to C. albicans infection had signifcantly decreased levels of SCFAs in the cecal contents, which is in agreement
with previous fndings14.
Next, we examined if alterations in the levels of SCFAs as a result of antibiotic treatment actually play a role in
the growth and morphogenesis of C. albicans, leading to increased GI colonization in cefoperazone-treated mice.
Te ability for C. albicans to cause infection is associated with its morphological switching from yeast to virulent
hyphae and, therefore, inhibition of the morphological plasticity of C. albicans would substantially reduce its
pathogenic potential46–52. While the reported cecal concentrations of SCFAs vary considerably based on diferent
factors including detection methods in addition to the age and diet of mice53,54, we decided to use the average in
vivo concentrations of SCFAs for the in vitro assays that correlate to published in vivo levels found in the cecum
of mice and humans39–42. Our results indicate that average in vivo concentration of SCFAs (acetic acid: 25 mM,
butyric acid: 12.5 mM, and propionic acid: 12.5 mM)39–42 found in the control mice exhibit signifcant inhibitory
efects on C. albicans growth in vitro, whereas the in vivo concentrations of SCFAs found in the antibiotic-treated
mice (acetic acid: 12.5 mM, butyric acid: 3.25 mM, and propionic acid: 3.25 mM)14 in the in vitro assays had
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only minimal efects on the growth of C. albicans. Using in vivo cecal concentrations of SCFAs found in C.
albicans-resistant mice, we also found signifcant inhibition of the morphogenesis of C. albicans in vitro39–42.
Collectively, our in vivo and in vitro results along with previous fndings demonstrate that antibiotic-induced
decreases in the levels of SCFAs in the cecum potentially allow C. albicans to grow and colonize in the gut14.
SCFAs inducing an acidic environment due to their dissociative properties55 may be a factor in their inhibitory
efects on C. albicans growth and morphogenesis. Terefore, we investigated if inhibitory efects of SCFAs on C.
albicans growth and morphogenesis are due to changes in environmental pH levels. Our results along with previous fndings indicate that C. albicans can actively neutralize an environmental pH and a SCFA-induced change
in pH levels does not considerably afect C. albicans growth2,56. Previous studies also indicate that under neutral
conditions, SCFAs exist in the anion form and do not exhibit antimicrobial activity, which is in agreement with
the lack of growth inhibition observed in RPMI media containing SCFAs that was bufered to pH 7.0057–59. Taken
together, our results along with previous fndings2,56–59 suggest that (i) SCFA-mediated inhibition of C. albicans
growth was not likely due to an alteration in environmental pH levels and (ii) the undissociated acidic form of
SCFAs is required for inhibitory activity.
Next, we examined the efect of pH on C. albicans morphogenesis. We found that acidic pH signifcantly
inhibits C. albicans morphogenesis, which is in agreement with reports that highlight the dynamic of acidic
conditions impeding C. albicans morphogenesis, while neutral and alkaline conditions induce morphogenesis47,56,60–62. SCFA-induced inhibition of C. albicans morphogenesis may be due in part to the generation of an
acidic environment; however, we report a signifcant diference in the morphogenic inhibition of SCFAs when
compared to pH-adjusted RPMI control groups. Taken together, these results indicate that the inhibitory efects of
SCFAs on C. albicans morphogenesis are not limited to alteration in environmental pH levels, and other unknown
mechanisms are involved. Although SCFA-induced fungal cell death was not a potential inhibitory mechanism in
the hyphae and bioflm formation, it remains unclear if the fungistatic efects of SCFAs may play a role in inhibiting hyphae and bioflm formation as a function of general growth arrest mechanisms30. Terefore, future studies
to understand the mechanisms behind the SCFA-mediated efects on C. albicans growth and morphogensis are
important to understand its pathogenesis and to develop novel therapeutic approaches.
Diverse microbes in the gut possess the ability to produce SCFAs. Among these, Bacteroides,
Ruminococcaceae, Lachnospiraceae, Clostridia, Prevotella, Oscillospira and Verrucomicrobia (Akkermansia
muciniphila), and Faecalibacteria are most commonly associated with the production of SCFAs21,37. Fan et al.
observed that bacteroides including Blautia producta and Bacteroides thetaiotaomicron directly afect C. albicans
colonization through SCFAs2. Our recent studies found that the probiotics interventions increase the SCFAs production by modulating human and mice gut microbiome63. Te role of microbial-derived SCFAs in contributing
to the host’s defense mechanisms against enteric pathogens has been previously reported,20,37 highlighting the
importance of the ability for SCFAs to inhibit pathogenic growth by maintaining the pH gradient in the colon,
among other factors including immune cell homeostasis. Terefore, future studies including characterization of
probiotic or commensal bacteria to enhance the abundance of SCFA levels may form a novel approach to prevent
and treat C. albicans colonization and subsequent pathogenesis.
Antibiotic treatment signifcantly alters SCFA levels in the gut; however, the composition and concentration of
other critical gut metabolites including bile acids are also afected13,14,17,18. Recently, we have shown that bile acids
play an important role in controlling C. albicans growth and morphogenesis17,18. We previously demonstrated
that treatment with in vivo concentrations of the primary conjugated bile acid taurocholic acid (TCA) (0.0125%)
promotes C. albicans growth and morphogenesis, whereas treatment with in vivo concentrations of secondary
bile acids deoxycholic acid (DCA [0.05%]) and lithocholic acid (LCA [0.01%]) inhibit C. albicans growth and
morphogenesis in vitro17,18. Terefore, understanding the role of various gut metabolites in the GI colonization of
C. albicans will expand our knowledge on C. albicans pathogenesis. In addition, this may form a strong foundation for eforts to use commensal bacteria to modulate gut metabolites to prevent and treat C. albicans infections.

Materials and Methods

Strains and reagents. Candida albicans ATCC 10231 was purchased from ATCC. Candida albicans SC5314
was kindly provided by Dr. Andrew Koh from University of Texas Southwestern Medical Center2. Media used
in this study included RPMI 1640 (Gibco, MA), MOPS (Sigma, MO), YPD Agar (BD Biosciences, CA), and
Fetal Bovine Serum (Atlanta Biologicals, GA). Short-chain fatty acids (acetic acid, butyric acid, and propionic
acid) were purchased from Sigma Aldrich (MO). Mice were purchased from Te Jackson Laboratory (ME).
Cefoperazone was purchased from Sigma Aldrich (MO). Other materials were purchased as indicated: mouse
oral gavages (Kent Scientifc, MA), vancomycin (Alfa Aesar, MA), gentamicin (Acros Organics, NJ), paraformaldehyde (Alfa Aesar, MA), and glycerol (DOT Scientifc, MI).
Cefoperazone treatment and C. albicans infection in mice.

Female C57BL/6J mice (5–6 mice per
group) were supplemented with sterile water with or without cefoperazone (0.5 mg/mL)64. Cefoperazone water
was replaced every two days. Afer 7 days of antibiotic treatment, mice were either sacrifced for SCFA metabolite
analysis or infected with C. albicans SC5314 via oral gavage at a dose of 4.25 × 108 CFU per mice31. Afer 5 days
of infection, fecal samples were collected from individual mice to determine the fungal load. Briefy, fecal pellets
were weighed and homogenized in PBS and the supernatant was plated onto YPD agar plates containing 0.1 mg/
mL gentamicin and 0.010 mg/mL vancomycin2. Afer 24 hours of incubation, the colonies were counted and the
fungal load (CFU/gram) was determined for individual mice. Te Institutional Animal Care and Use Committee
(IACUC) at Midwestern University approved this study under MWU IACUC Protocol #2894. Te MWU animal
care policies follow the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals and
the policies laid out in the Animal Welfare Act (AWA). Trained animal technicians performed animal husbandry
in our IACUC monitored animal care facility in the Foothills Science Building.
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Quantifying SCFAs levels in the cecal content. Equal amount of snap frozen cecal content was weighed,

dissolved in HPLC grade water and supernatants were collected afer centrifugation (12,000 g, 10 min), while
processing on ice. Concentrations of SCFAs (acetate, propionate and butyrate) were determined using a HPLC
system (Waters-2695 Alliance HPLC system, Waters Corporation, Milford, MA, USA) equipped with Aminex
HPX-87H column (Bio-Rad Laboratories, Hercules, CA) and DAD detector (210 nm), and eluting with H2SO4
(0.005 N) mobile phase with a fow rate of 0.6 ml/min at 25 °C, as described elsewhere63,65,66.

Growth assay.

Te growth of C. albicans ATCC 10231 and SC 5314 was measured as previously described,17
using pH-adjusted controls titrated with HCl as described below (Table 1).

pH-adjusted control RPMI media for in vitro assays.

pH-adjusted controls were used for all in vitro
experiments involving SCFAs. Briefy, pH was measured using a Fisherbrand Accumet AE150 pH meter (Termo
Fisher, MA). Te pH meter was calibrated each time before use using Orion calibration bufers (Termo Fisher,
MA). pH was adjusted for short-chain fatty acid treatments using acetic acid as the reference point since acetic,
butyric, and propionic acid share similar experimental pKas (4.76, 4.83, and 4.87, respectively55), with acetic acid
having the lowest pKa and thus most potent efect on pH via dissociation55. pH was adjusted using HCl for in vitro
assays as described in Table 1. For growth and bioflm assays, RPMI media was adjusted with HCl to match the
pH values of SCFAs. Similarly, for hyphae and germ tube assays, RPMI media supplemented with 30% FBS was
adjusted with HCl as described in Table 1.

Biofilm assay.

C. albicans (ATCC 10231 and SC5314) with an inoculum size of 1.7 × 106–3.2 × 106 CFU/mL
was used to form the bioflm and the metabolic activity of fungal cells in the bioflm was carried out using MTS
assay as previously described17. Te efect of SCFAs on C. albicans cell viability was assessed by incubating fungal
cells with the indicated concentration of SCFAs at 37 °C for 48 hours in 4-mL tubes. Appropriate pH-adjusted
RPMI control media was used as described in Table 1. Afer 48 hours of incubation, the cell suspension was plated
onto YPD agar plates and the CFUs were counted to determine the efect of SCFAs on C. albicans cell viability.

Germ tube and hyphae assays.

Te efect of SCFAs on C. albicans germ tube and hyphae formation was
assessed as previously described17. For the germ tube assay, C. albicans (ATCC 10231) with an inoculum size of
3.48 × 106 CFU/mL was incubated with or without SCFAs for 2 hours and the percentage of germ tubes formed
were quantifed at 20X magnifcation17. Similarly, C. albicans ATCC 10231 and SC 5314 strains (3.34 × 107–
4.60 × 108 CFU/mL) were incubated with or without SCFAs and the C. albicans hyphae formation and attachment were determined using bright feld microscopy and crystal violet assay as described before17. Te crystal
violet assay was adopted using a protocol defned by Abe et al.67,68 Further, the efect of SCFAs on C. albicans cell
viability under germ tube and hyphae assay conditions was assessed by incubating fungal cells with the indicated
concentration of SCFAs at 37 °C for 48 hours in 4-mL tubes. Afer 48 hours of incubation, cell suspensions were
plated onto YPD agar plates and the CFUs were counted to determine the efect of SCFAs on C. albicans cell viability. Appropriate pH-adjusted RPMI control media was used as described in Table 1.

Statistical analyses. The Student t-test was utilized for statistical analyses using GraphPad Prism 6.0
(GraphPad Sofware, La Jolla, CA) with p-values of (* ≤ 0.05, ** ≤ 0.01) being considered signifcant.

Data Availability

Te datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
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